These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23022081)

  • 1. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice.
    Ago Y; Yano K; Araki R; Hiramatsu N; Kita Y; Kawasaki T; Onoe H; Chaki S; Nakazato A; Hashimoto H; Baba A; Takuma K; Matsuda T
    Neuropharmacology; 2013 Feb; 65():29-38. PubMed ID: 23022081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression.
    Ago Y; Arikawa S; Yata M; Yano K; Abe M; Takuma K; Matsuda T
    Neuropharmacology; 2008 Dec; 55(8):1355-63. PubMed ID: 18796307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
    Chaki S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.
    Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM
    J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist.
    Karasawa J; Shimazaki T; Kawashima N; Chaki S
    Brain Res; 2005 Apr; 1042(1):92-8. PubMed ID: 15823257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression.
    Koike H; Fukumoto K; Iijima M; Chaki S
    Behav Brain Res; 2013 Feb; 238():48-52. PubMed ID: 23098797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.
    Koike H; Chaki S
    Behav Brain Res; 2014 Sep; 271():111-5. PubMed ID: 24909673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.
    Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT
    Fukumoto K; Iijima M; Funakoshi T; Chaki S
    Neuropharmacology; 2018 Jul; 137():96-103. PubMed ID: 29738849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test.
    Fukumoto K; Iijima M; Chaki S
    Psychopharmacology (Berl); 2014 Jun; 231(11):2291-8. PubMed ID: 24402133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.
    Fukumoto K; Iijima M; Chaki S
    Neuropsychopharmacology; 2016 Mar; 41(4):1046-56. PubMed ID: 26245499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.
    Koike H; Iijima M; Chaki S
    Neuropharmacology; 2011 Dec; 61(8):1419-23. PubMed ID: 21903115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the mechanism of antidepressant-like action of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression.
    Campo B; Kalinichev M; Lambeng N; El Yacoubi M; Royer-Urios I; Schneider M; Legrand C; Parron D; Girard F; Bessif A; Poli S; Vaugeois JM; Le Poul E; Celanire S
    J Neurogenet; 2011 Dec; 25(4):152-66. PubMed ID: 22091727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039.
    Pałucha-Poniewiera A; Wierońska JM; Brański P; Stachowicz K; Chaki S; Pilc A
    Psychopharmacology (Berl); 2010 Dec; 212(4):523-35. PubMed ID: 20703449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram.
    Dong C; Tian Z; Fujita Y; Fujita A; Hino N; Iijima M; Hashimoto K
    Pharmacol Biochem Behav; 2022 Jan; 212():173316. PubMed ID: 34968554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495.
    Podkowa K; Podkowa A; Sałat K; Lenda T; Pilc A; Pałucha-Poniewiera A
    Neuropharmacology; 2016 Dec; 111():169-179. PubMed ID: 27569995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
    Fell MJ; Witkin JM; Falcone JF; Katner JS; Perry KW; Hart J; Rorick-Kehn L; Overshiner CD; Rasmussen K; Chaney SF; Benvenga MJ; Li X; Marlow DL; Thompson LK; Luecke SK; Wafford KA; Seidel WF; Edgar DM; Quets AT; Felder CC; Wang X; Heinz BA; Nikolayev A; Kuo MS; Mayhugh D; Khilevich A; Zhang D; Ebert PJ; Eckstein JA; Ackermann BL; Swanson SP; Catlow JT; Dean RA; Jackson K; Tauscher-Wisniewski S; Marek GJ; Schkeryantz JM; Svensson KA
    J Pharmacol Exp Ther; 2011 Jan; 336(1):165-77. PubMed ID: 20947638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801.
    Farley S; Dumas S; El Mestikawy S; Giros B
    Neuropharmacology; 2012 Jan; 62(1):503-17. PubMed ID: 21945287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.